Association between the number of glutamine (Gln) repetitions and healthy/pathologic state in 114 canine blood and MCT samples.

<p>Pearson χ² test (p = 0.3454; not significant).</p

Sequence alignment between dog, cat, human, mouse and rat specific glutamine-rich regions located in exon 3 and 11 of TET2 gene.

<p>The image was obtained using the tool ClustalW2 (<a href="http://www.ebi.ac.uk/Tools/msa/clustalw2/" target="_blank">http://www.ebi.ac.uk/Tools/msa/clustalw2/</a>).</p

List of genetic variations grouped for gene, relative population frequency and allelic frequencies in the MCT cohort of samples.

<p>List of genetic variations grouped for gene, relative population frequency and allelic frequencies in the MCT cohort of samples.</p

List of target genes and percentage of protein sequence identity between dog and other reference species (<i>Homo sapiens</i>, <i>Felis catus</i>, <i>Mus musculus</i>, <i>Rattus norvegicus</i>).

<p>NA: sequence not available in the databases.</p><p>List of target genes and percentage of protein sequence identity between dog and other reference species (<i>Homo sapiens</i>, <i>Felis catus</i>, <i>Mus musculus</i>, <i>Rattus norvegicus</i>).</p

List of genetic variations detected in the glutamine rich region of TET2 exon 11 with relative population frequency and total glutamine residues number in the 75 MCT samples.

<p>List of genetic variations detected in the glutamine rich region of TET2 exon 11 with relative population frequency and total glutamine residues number in the 75 MCT samples.</p

Forward (F) and reverse (R) primer sequences of canine genes included in the present study and used for polymerase chain reaction with the corresponding annealing temperature and product length.

<p>Forward (F) and reverse (R) primer sequences of canine genes included in the present study and used for polymerase chain reaction with the corresponding annealing temperature and product length.</p

Demographic, clinical and biological characteristics of patients with myeloid and lymphoid SM-AHNMD patients at inclusion.

1<p>C-findings according to WHO classification.</p>2<p>including fatigue, headache, flushes, fever, hypotension, choc, syncope, WHO; world health organization, CM; cutaneous mastocytosis, AHNMD; associated clonal hematologic non-mast cell lineage disease, UP; urticaria pigmentosa, TEMP; telengietasia eruptive macularis persistans, DCM; diffuse cutaneous mastocytosis, BMD; bone mineral density.</p

Primer positions are indicated from the c-Kit sequence published through the NCBI accession number X06182.

<p>Primer positions are indicated from the c-Kit sequence published through the NCBI accession number X06182.</p

Relationship between phenotype and genotype in patients with mastocytosis according to their age of onset.

<p>Data are expressed in number (percentage).</p

Exons 8 through 13 and 17 mutations according to mastocytosis age of onset.

<p>Data are expressed in number (percentage), 816: substitution of valine in 816 codon of <i>c-kit</i>, Other mutations: mutation in exons 8 through 13. WT: absence of mutation in exons 8 through 13 and 17. Complete genotype was not available for 4 816 WT patients; 1 patient in group 1A, 1 in group 1B and 2 in group 2.</p